Maricann Group Inc. appointed Scott Langille as CFO, effective Oct. 2, subject to regulatory approval.
Previously, the company's CEO Ben Ward had taken the additional role of interim CFO.
Langille was formerly CFO of Tribute Pharmaceuticals Canada Inc., which was sold to Pozen Inc. in February 2016 for $160 million to form Aralez Pharmaceuticals Inc.